172 related articles for article (PubMed ID: 24084213)
1. Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan.
Kim CO; Lee HW; Oh ES; Seong SJ; Kim DY; Lee J; Ahn SH; Yoon YR; Cho CM; Park MS
J Cardiovasc Pharmacol; 2013 Dec; 62(6):524-9. PubMed ID: 24084213
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.
Yi S; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2011 Jun; 57(6):682-9. PubMed ID: 21394036
[TBL] [Abstract][Full Text] [Related]
4. Effect of age on the pharmacokinetics of fimasartan (BR-A-657).
Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Cho JY; Yu KS; Yoon YR
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1337-44. PubMed ID: 21950382
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
[TBL] [Abstract][Full Text] [Related]
6. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.
Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS
Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916
[TBL] [Abstract][Full Text] [Related]
7. The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan.
Gu N; Cho JY; Shin KH; Jang IJ; Rhee MY
Drug Des Devel Ther; 2016; 10():1525-31. PubMed ID: 27143858
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers.
Jeon H; Lim KS; Shin KH; Kim J; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2012 Jan; 59(1):84-91. PubMed ID: 21934629
[TBL] [Abstract][Full Text] [Related]
9. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin.
Kim JW; Yi S; Kim TE; Lim KS; Yoon SH; Cho JY; Lee MG; Song IS; Shin SG; Jang IJ; Yu KS
J Clin Pharmacol; 2013 Jan; 53(1):75-81. PubMed ID: 23400746
[TBL] [Abstract][Full Text] [Related]
10. Fimasartan, a novel angiotensin II receptor antagonist.
Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects
.
Park DB; Jang K; Lee JW; Park CW; Lee BH; Kim MG; Jeon JY
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):286-294. PubMed ID: 28079517
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.
Lee J; Rhee SJ; Lee S; Yu KS
Drug Des Devel Ther; 2018; 12():787-794. PubMed ID: 29670335
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers.
Kang WY; Kim EH; Seong SJ; Gwon MR; Yang DH; Kim HJ; Lim MS; Lee HW; Yoon YR
Int J Clin Pharmacol Ther; 2016 Dec; 54(12):992-1003. PubMed ID: 27668695
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
Bulitta JB; Paik SH; Chi YH; Kim TH; Shin S; Landersdorfer CB; Jiao Y; Yadav R; Shin BS
Eur J Pharm Sci; 2017 Sep; 107():32-44. PubMed ID: 28599987
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.
Kang WY; Lee HW; Gwon MR; Cho S; Shim WS; Lee KT; Yang DH; Seong SJ; Yoon YR
Drug Des Devel Ther; 2020; 14():2101-2111. PubMed ID: 32546973
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets.
Hwang JG; Yu KS; Lee S
Drug Des Devel Ther; 2020; 14():1953-1961. PubMed ID: 32546962
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects.
Kang WY; Seong SJ; Ohk B; Gwon MR; Kim BK; Cho S; Shim WS; Lee KT; Kim EH; Yang DH; Lee HW; Yoon YR
Drug Des Devel Ther; 2018; 12():3607-3615. PubMed ID: 30464392
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
de Zeeuw D; Remuzzi G; Kirch W
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
[TBL] [Abstract][Full Text] [Related]
20. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
